EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer

EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
复制标题

DOI:
10.1016/s0092-8674(03)00930-9
复制
发表时间:
2003-11-26
期刊:
影响因子:
64.5
通讯作者:
Kouzarides, T
Kouzarides, T
中科院分区:
生物学1区
文献类型:
--
作者:
Hughes-Davies, L;Huntsman, D;Kouzarides, T

文献摘要

被引文献

相似文献

BRCA2基因在家族性乳腺癌和卵巢癌中发生突变,其产物与DNA修复和转录调控有关。在这里,我们确定了一种蛋白质,EMSY,它结合BRCA2的区域内(外显子3)在癌症中删除。EMSY能够沉默BRCA 2外显子3的激活潜力,与染色质调节因子HP 1 β和BS 69相关,并定位于DNA损伤后的修复位点。EMSY定位于染色体11q13.5,这是一个已知与乳腺癌和卵巢癌有关的区域。我们发现EMSY基因几乎只在散发性乳腺癌(13%)和高级别卵巢癌(17%)中扩增。此外,EMSY扩增与较差的生存率相关,特别是在淋巴结阴性乳腺癌中,这表明它可能具有预后价值。散发性EMSY扩增和家族性BRCA2缺失之间的显著临床重叠暗示了散发性乳腺癌和卵巢癌中的BRCA2通路。
The BRCA2 gene is mutated in familial breast and ovarian cancer, and its product is implicated in DNA repair and transcriptional regulation. Here we identify a protein, EMSY, which binds BRCA2 within a region (exon 3) deleted in cancer. EMSY is capable of silencing the activation potential of BRCA2 exon 3, associates with chromatin regulators HP1beta and BS69, and localizes to sites of repair following DNA damage. EMSY maps to chromosome 11q13.5, a region known to be involved in breast and ovarian cancer. We show that the EMSY gene is amplified almost exclusively in sporadic breast cancer (13%) and higher-grade ovarian cancer (17%). In addition, EMSY amplification is associated with worse survival, particularly in node-negative breast cancer, suggesting that it may be of prognostic value. The remarkable clinical overlap between sporadic EMSY amplification and familial BRCA2 deletion implicates a BRCA2 pathway in sporadic breast and ovarian cancer.